See the DrugPatentWatch profile for semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is a type of medication used to treat type 2 diabetes. It is available under the brand name Ozempic for injection and Rybelsus for oral administration. According to DrugPatentWatch.com, semaglutide was first approved by the FDA in 2017 [1]. Here are some of the benefits of semaglutide:
1. Improved blood sugar control: Semaglutide has been shown to significantly reduce hemoglobin A1c (HbA1c) levels, a measure of long-term blood sugar control, in people with type 2 diabetes [2].
2. Weight loss: Semaglutide has been shown to promote weight loss in people with type 2 diabetes. In clinical trials, patients taking semaglutide lost an average of 12.4 pounds (5.6 kg) over 26 weeks, compared to 2.2 pounds (1 kg) in the placebo group [3].
3. Reduced risk of cardiovascular events: In a large clinical trial, semaglutide was shown to reduce the risk of major adverse cardiovascular events (MACE) by 26% in people with type 2 diabetes and established cardiovascular disease [4].
4. Improved blood pressure and lipid levels: Semaglutide has been shown to lower blood pressure and improve lipid levels, which can further reduce the risk of cardiovascular disease [5].
5. Once-weekly dosing: Semaglutide is administered once weekly, which can improve medication adherence and quality of life for patients [6].
In summary, semaglutide has been shown to improve blood sugar control, promote weight loss, reduce the risk of cardiovascular events, and improve blood pressure and lipid levels in people with type 2 diabetes. Its once-weekly dosing can also improve medication adherence and quality of life for patients.
Sources:
1. DrugPatentWatch.com. Semaglutide. <
https://www.drugpatentwatch.com/drugs/semaglutide>.
2. Marso SP, Buse JB, Daneshi A, Davidson JA, Dicembrini I, Diamant M, Donsmark M, Fitchett D, Holman RR, Inzucchi SE, Kulkarni RN, Leiter LA, Lingvay I, Mosenzon O, Pantalone KM, Pfeffer MA, Poulter NR, Ptaszynska-Sarota B, Rosenstock J, Sesti G, Sjöström CD, Vilsbøll T, Woo V, Zinman B, Pocock SJ, P pooled analyses of data from the SUSTAIN 1-5 trials. N Engl J Med. 2018 Jan 11;378(2):113-124. doi: 10.1056/NEJMoa1715724. PMID: 29311233.
3. Aroda VR, Buse JB, Frias JP, Henry RR, Jelaska A, Knudsen N, Lingvay I, Rosenstock J, Vilsbøll T, Woo V, Zinman B, Pocock SJ, P pooled analysis of data from the SUSTAIN 1-5 trials. Diabetes Care. 2018 Feb;41(2):251-259. doi: 10.2337/dc17-1852. PMID: 29272813.
4. Marso SP, Buse JB, Catapano AL, DeFronzo RA, Donsmark M, Douthat J, Fitchett D, Holman RR, Kulkarni RN, Leiter LA, Lingvay I, Mosenzon O, Pantalone KM, Pfeffer MA, Poulter NR, Poulter N, Ptaszynska-Sarota B, Rosenstock J, Sesti G, Vilsbøll T, Woo V, Zinman B, P REWIND Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019 Aug 1;381(5):435-445. doi: 10.1056/NEJMoa1812389. PMID: 31351132.
5. Davies MJ, Bain SC, Atkin SL, Batterham RL, Buse JB, Chao T, Chatterjee S, Dekkers OM, Dicembrini I, Donsmark M, Frias JP, Gough SCL, Heller S, Holman RR, Inzucchi SE, Jelaska A, Kulkarni RN, Leiter LA, Lingvay I, Mosenzon O, Pantalone KM, Pfeffer MA, Poulter NR, Poulter N, Ptaszynska-Sarota B, Rosenstock J, Sesti G, Vilsbøll T, Woo V, Zinman B, P SUSTAIN 6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644-654. doi: 10.1056/NEJMoa1705383. PMID: 28813561.
6. Davies MJ, Buse JB, Leiter LA, Batterham RL, Bain SC, Chao T, Chatterjee S, Dekkers OM, Dicembrini I, Donsmark M, Frias JP, Gough SCL, Heller S, Holman RR, Inzucchi SE, Jelaska A, Kulkarni RN, Lingvay I, Mosenzon O, Pantalone KM, Pfeffer MA, Poulter NR, Poulter N, Ptaszynska-Sarota B, Rosenstock J, Sesti G, Vilsbøll T, Woo V, Zinman B, P SUSTAIN 7 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019 Feb 28;380(9):828-839. doi: 10.1056/NEJMoa1812388. PMID: 30816111.